Klaria Pharma

The year in brief

- Net sales amounted to 2.2 MSEK (8.5 MSEK)

- Other operating income amounted to 0.1 MSEK (0.5 MSEK)

- R&D costs amounted to 22.1 MSEK (25.0 MSEK)

- Profit/loss after tax amounted to -47.8 MSEK (-35.8 MSEK)

- Earnings per share amounted to -0.38 SEK (-0.36 SEK)

- Cash flow from operations amounted to -11.9 MSEK (-9.1 MSEK)

- Shareholder’s equity as of December 31, 2024 amounted to 3.3 MSEK (41.1 MSEK)

- Cash and cash equivalents as of December 31, 2024 amounted to 0.6 MSEK (1.2 MSEK)